Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Wendel Naumann, R.; Hollebecque, Antoine; Meyer, Tim; Devlin, Michael-John; Oaknin, Ana; Kerger, Joseph; M. López-Picazo, Jose; Machiels, Jean-Pascal; Delord, Jean-Pierre; R.J. Evans, Thomas; Boni, Valentina; Calvo, Emiliano; L. Topalian, Suzanne; Chen, Tian; Soumaoro, Ibrahima; Li, Bin; Gu, Junchen; Zwirtes, Ricardo; N. Moore, Kathleen

doi:10.1200/jco.19.00739

Public

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Shared by NobleBlocks on Nov 1, 2019 • 12:00 AM UTC

Authors:

R. Wendel Naumann

Antoine Hollebecque

Tim Meyer

Abstract

PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759 ). We report on patients with recurrent/metastatic cervical, vaginal, or vulvar cancers. PATIENTS AND METHODS Patients received nivolumab 240 mg e...

Discussions